I'm LongbridgeAI, I can summarize articles.Boundless Bio reported a widened Q2 FY26 GAAP net loss of $23.69 million, up from $15.68 million year-over-year, with operating losses reaching $24.38 million due to increased R&D and G&A expenses. The company held $72.6 million in cash but reported no revenue. Concurrently, Boundless Bio merged with Serapha, anticipates a $44-$48 million pre-closing dividend, and reduced its workforce by approximately 75%.
- Boundless Bio posted a GAAP net loss of $23.69 million for the quarter ended June 30, 2026, widening from $15.68 million a year earlier. * Operating loss widened to $24.38 million from $17.06 million, as total operating expenses climbed to $24.38 million from $17.06 million. * R&D expense rose to $13.97 million from $12.22 million; G&A jumped to $10.41 million from $4.84 million. * The company ended the quarter with $72.6 million in cash, cash equivalents and short-term investments, with no revenue reported. * Boundless Bio entered a merger agreement with Serapha on June 22, expects a $44 million-$48 million pre-closing cash dividend, and cut its workforce by about 75%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-339093), on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here